Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma. This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...

A multiple myeloma survivor discusses how continued minimal residual disease negativity made her feel more confident in coming off of maintenance therapy. After undergoing treatment — including a stem ...

SAGA will present new data supporting Pathlight, its tumor-informed, structural variant-based ctDNA platform, across ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...

A two-time breast cancer survivor who was diagnosed with chronic lymphocytic leukemia in 2020 discussed her belief in the power of minimal residual disease testing. Two-time breast cancer survivor Sue ...

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...

Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...

Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...